SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
TheraVida, Inc. Announces Positive Top-Line Phase 2 Results for Tolenix™ (THVD-201) in Patients with Overactive Bladder and Urge Urinary Incontinence
Your Message